For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 180d
$1,105.00
Thesis
Eli Lilly markets the tirzepatide products Mounjaro and Zepbound, which target type 2 diabetes and obesity. As a diversified pharmaceutical company, it also advances an oral GLP-1 pipeline alongside its injectable franchise.
Catalysts
- Oral GLP-1 candidate clinical readouts
- Manufacturing capacity expansion for tirzepatide
- Label expansions for Mounjaro and Zepbound